--- title: "Creatv 宣佈將在 2026 年美國臨牀腫瘤學會（ASCO）會議上進行五項臨牀數據展示" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/285223983.md" description: "Creatv Bio 是一家癌症診斷血液檢測公司，宣佈將在 2026 年美國臨牀腫瘤學會（ASCO）年會上進行一場海報展示和四個海報摘要，會議定於 2026 年 5 月 29 日至 6 月 2 日在芝加哥舉行。展示內容包括關於血液生物標誌物在預測轉移性乳腺癌無進展生存期方面的研究，以及與製藥合作伙伴合作使用 LifeTracDx®血液檢測的研究。該公司旨在開發癌症治療的診斷工具，並提供持續監測以優化治療方案" datetime: "2026-05-05T14:20:33.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285223983.md) - [en](https://longbridge.com/en/news/285223983.md) - [zh-HK](https://longbridge.com/zh-HK/news/285223983.md) --- # Creatv 宣佈將在 2026 年美國臨牀腫瘤學會（ASCO）會議上進行五項臨牀數據展示 MONMOUTH JUNCTION, N.J., May 5, 2026 /PRNewswire/ -- Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv"), a cancer diagnostic blood testing company, is pleased to announce one poster presentation and four poster abstracts in conjunction with it's pharmaceutical company collaborators at the upcoming 2026 ASCO Annual Meeting, May 29-June 2, 2026, McCormick Place, Chicago, Illinois. **Abstract Title:** Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis. **Abstract:** 2652 **Session Title:** Developmental Therapeutics—Immunotherapy **Poster Board:** 442 **Date and Time:** May 30, 2026, 1:30 PM – 4:30 PM CDT **_Poster Abstracts in Collaboration with BriaCell, a_** **_clinical-stage immuno-oncology drug company,_** **Abstract Title:** Monitoring PD-L1 expression in circulating cancer associated cells for prediction of clinical outcomes in metastatic breast cancer patients treated with immune checkpoint inhibitors. **Abstract:** e14535 **Abstract Title:** Liquid biopsy to stratify metastatic breast cancer progression risk using multi-analyte cell subtyping prior to systemic therapy. **Abstract:** e15525 **_Poster Abstracts in Collaboration with CytoDyn, a biotechnology company developing innovative treatments for cancer._** **Abstract Title:** Safety and 5-year survival following treatment with leronlimab plus physician's choice combination therapy in patients with metastatic triple-negative breast cancer. **Abstract:** e14535 **Abstract Title:** Leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab for patients with refractory metastatic colorectal cancer (mCRC): The phase 2 CLOVER study. **Abstract:** e13109 Creatv Bio's LifeTracDx® blood test, described in the abstracts above, was used in the various studies to rapidly develop companion/complementary diagnostic tools for specific cancer therapies and provided continuous monitoring of cancer patients for pharmaceutical companies to optimize therapy regimes. **About Creatv Bio** Creatv Bio is a CLIA-certified cancer diagnostics company providing laboratory testing services to pharmaceutical and research partners, as well as to patients for research and investigational purposes. The LifeTracDx® blood test is an analytically validated assay under ongoing research and development. Current research applications include evaluation of circulating biomarkers in oncology to support translational and exploratory studies. The assay is intended for research and investigational use only and is not intended for use in clinical diagnosis, prognosis, treatment selection, or disease monitoring. For our research studies and complete listing of peer-reviewed publications and scientific posters, please visit our website at creatvbio.com. **Creatv contacts**: **Daniel L Adams** **Ron Baker** Chief Scientific Officer Chief Business Officer dan@creatvmicrotech.com ron@creatvmicrotech.com 732-783-7132 (office) 301-785-5185 (mobile) View original content to download multimedia:https://www.prnewswire.com/news-releases/creatv-announces-five-clinical-data-presentations-at-asco-2026-302762698.html SOURCE Creatv MicroTech, Inc. ### 相關股票 - [SONN.CVR.US](https://longbridge.com/zh-HK/quote/SONN.CVR.US.md) - [MBIO.US](https://longbridge.com/zh-HK/quote/MBIO.US.md) - [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) - [BCTX.US](https://longbridge.com/zh-HK/quote/BCTX.US.md) - [BCTXZ.US](https://longbridge.com/zh-HK/quote/BCTXZ.US.md) - [BCTXW.US](https://longbridge.com/zh-HK/quote/BCTXW.US.md) - [CYDY.US](https://longbridge.com/zh-HK/quote/CYDY.US.md) - [BCTXL.US](https://longbridge.com/zh-HK/quote/BCTXL.US.md) ## 相關資訊與研究 - [巨生醫獲 SelectUSA 醫療科技組金牌 啟動美國 A 輪募資目標 1000 萬美元](https://longbridge.com/zh-HK/news/286905054.md) - [鉅亨速報 - Factset 最新調查：Roivant Sciences LtdROIV-US 的目標價調升至 38 元，幅度約 8.57%](https://longbridge.com/zh-HK/news/287126179.md) - [瑞銀上調爵士製藥評級：核心業務韌性強勁，新藥 Ziihera 成增長引擎](https://longbridge.com/zh-HK/news/286920691.md) - [健康綜述：廣泛使用的哮喘藥物或可提升癌症免疫療法療效](https://longbridge.com/zh-HK/news/286957357.md) - [Tevogen Bio Q1 運營虧損收窄 48%，推進 AI 平台與細胞療法管線](https://longbridge.com/zh-HK/news/287086570.md)